Opinions

Findings from the NeoADAURA and the CheckMate 816 provide novel insights on the role of neoadjuvant osimertinib and nivolumab in the perioperative setting

Positive findings from the CAPTURE and AMPLITUDE trials highlight the importance of early testing patients for BRCA and HRR mutations

Recent research indicates that older age remains a barrier to accessing optimal treatment, despite a growing number of patients over 70 with ovarian and endometrial tumours

Novel evidence demonstrates the clinical utility of circulating tumour DNA in patients with HR+/HER2- cancers harbouring ESR1 and PIK3CA mutations 

Findings from recently presented studies support an upfront integration of ADCs in the treatment course, but some key questions are pending

Two studies investigating efficacy of bispecific T-cell engager tarlatamab and lurbinectedin–atezolizumab combination met their primary endpoints of survival

Recent studies have refined current knowledge on how to better treat this patient population, taking care of their unique needs and expectations

Defining patients most likely to respond, a better understanding of the host–tumour immune axis and clinical trials for specific subtypes are key to extending success

Adjuvant immunotherapy is still actual despite heterogeneity on its accessibility in Europe and fast advances in neoadjuvant immunotherapy

While strategies for drug de-escalation continue to be actively pursued, some challenges including insufficient funding of research still limit their applicability